Data on Astex Candidate - Analyst Blog

By
A A A

Astex Pharmaceuticals, Inc. ( ASTX ) recently presented data from the phase I portion (dose-escalation) of the SGI-110-01 study in patients with intermediate or high risk relapsed or refractory myelodysplastic syndromes (r/r MDS). The data was presented at the European Hematology Association (EHA).

15 intermediate or high risk r/r MDS (including chronic myelomonocytic leukemia) patients were enrolled in the study - the patients had been treated earlier with either Vidaza (azacitidine) or Dacogen (decitabine). About 40% of the patients had undergone treatment with both therapies. Six of the 15 patients achieved an overall response rate of 40%.

SGI-110 is currently in a phase I/II trial for MDS and acute myeloid leukemia (AML), and phase II trials for platinum resistant ovarian cancer and liver cancer. The phase II dose expansion study in patients who are treatment-naive to prior Vidaza or Dacogen therapy has so far enrolled 40 treatment naïve MDS patients. First data from phase II studies on platinum-resistant ovarian cancer and liver cancer is expected in 2014.

Astex is trying to develop a portfolio of cancer drugs, with candidates such as AT13387, SGI-110, AT7519, AT9283, and AT13148. Astex has started phase II studies with AT13387 in patients with refractory gastrointestinal stromal tumors (GIST), castration resistant prostate cancer (CPRC), and non-small cell lung cancer (NSCLC). First data from phase II studies on CRPC and NSCLC is expected in 2014.

Astex carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. ( SNTS ), Anika Therapeutics Inc. ( ANIK ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) look well positioned with a Zacks Rank #1 (Strong Buy).



ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

ASTEX PHARMACT (ASTX): Get Free Report


JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: ANIK , ASTX , JAZZ , SNTS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

72,116,831
  • $15.41 ▲ 0.13%
59,164,914
  • $6.35 ▲ 5.66%
39,692,077
  • $124.25 ▼ 0.14%
38,215,090
  • $24.84 ▲ 0.12%
36,287,253
  • $40.72 ▲ 0.16%
33,186,563
  • $13 ▲ 0.62%
31,877,837
    $27.13 unch
31,265,048
  • $5.58 ▼ 1.24%
As of 4/1/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com